4D Pharma, a biopharmaceutical company focusing on significant new therapeutic areas, plan to raise €46M to continue the development of its drugs candidates and to exploit its microbiome platform MicroRx. Will 4DPharma be the next UK’s microbiome leader?
This English company, founded in early 2014, has focused its current interests solely in the microbiome field and the discovery and development of bacteria as living biotherapeutics. This field, which is a new class of therapeutics, could deliver a significant step forward in the healthcare market, developing medicines showing efficacy with a greatly improved safety profile. In July 2014, the company raised €28.5M, taking the total raised to €99.7M, in order to develop its existing products: Thetanix and Rosburix, and Micro Rx, the company’s proprietary discovery platform.
Thetanix, a Paediatric Crohn’s Disease, will commence clinical trials in the second quarter of 2015. The company’s second product in development, Rosburix, received orphan drug designation from the FDA in August 2014 for the treatment of Paediatric Ulcerative Colitis (PUC).
4D’s intentions also include identifying,